Literature DB >> 23772273

Gastrointestinal complications of diabetes mellitus.

Babu Krishnan1, Shithu Babu, Jessica Walker, Adrian B Walker, Joseph M Pappachan.   

Abstract

Diabetes mellitus affects virtually every organ system in the body and the degree of organ involvement depends on the duration and severity of the disease, and other co-morbidities. Gastrointestinal (GI) involvement can present with esophageal dysmotility, gastro-esophageal reflux disease (GERD), gastroparesis, enteropathy, non alcoholic fatty liver disease (NAFLD) and glycogenic hepatopathy. Severity of GERD is inversely related to glycemic control and management is with prokinetics and proton pump inhibitors. Diabetic gastroparesis manifests as early satiety, bloating, vomiting, abdominal pain and erratic glycemic control. Gastric emptying scintigraphy is considered the gold standard test for diagnosis. Management includes dietary modifications, maintaining euglycemia, prokinetics, endoscopic and surgical treatments. Diabetic enteropathy is also common and management involves glycemic control and symptomatic measures. NAFLD is considered a hepatic manifestation of metabolic syndrome and treatment is mainly lifestyle measures, with diabetes and dyslipidemia management when coexistent. Glycogenic hepatopathy is a manifestation of poorly controlled type 1 diabetes and is managed by prompt insulin treatment. Though GI complications of diabetes are relatively common, awareness about its manifestations and treatment options are low among physicians. Optimal management of GI complications is important for appropriate metabolic control of diabetes and improvement in quality of life of the patient. This review is an update on the GI complications of diabetes, their pathophysiology, diagnostic evaluation and management.

Entities:  

Keywords:  Diabetes mellitus; Diabetic enteropathy; Diabetic gastroparesis; Esophageal complications; Gastrointestinal complications; Glycogenic hepatopathy; Nonalcoholic fatty liver disease

Year:  2013        PMID: 23772273      PMCID: PMC3680624          DOI: 10.4239/wjd.v4.i3.51

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  119 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years.

Authors:  Richard W McCallum; Zhiyue Lin; Jameson Forster; Katherine Roeser; Qingjiang Hou; Irene Sarosiek
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-23       Impact factor: 11.382

Review 3.  New esophageal function testing (impedance, Bravo pH monitoring, and high-resolution manometry): clinical relevance.

Authors:  Jason A Wilson; Marcelo F Vela
Journal:  Curr Gastroenterol Rep       Date:  2008-06

4.  Up-regulated expression of advanced glycation end-products and their receptor in the small intestine and colon of diabetic rats.

Authors:  Pengmin Chen; Jingbo Zhao; Hans Gregersen
Journal:  Dig Dis Sci       Date:  2011-11-06       Impact factor: 3.199

5.  Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

Authors:  Hellan Kang; Joel K Greenson; Jason T Omo; Cewin Chao; Debra Peterman; Lilian Anderson; Laura Foess-Wood; Mary A Sherbondy; Hari S Conjeevaram
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Cellular changes in diabetic and idiopathic gastroparesis.

Authors:  Madhusudan Grover; Gianrico Farrugia; Matthew S Lurken; Cheryl E Bernard; Maria Simonetta Faussone-Pellegrini; Thomas C Smyrk; Henry P Parkman; Thomas L Abell; William J Snape; William L Hasler; Aynur Ünalp-Arida; Linda Nguyen; Kenneth L Koch; Jorges Calles; Linda Lee; James Tonascia; Frank A Hamilton; Pankaj J Pasricha
Journal:  Gastroenterology       Date:  2011-02-04       Impact factor: 22.682

8.  Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

Authors:  Mireen Friedrich-Rust; William Rosenberg; Julie Parkes; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  BMC Gastroenterol       Date:  2010-09-09       Impact factor: 3.067

9.  Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.

Authors:  Mariana Lazo; Steven F Solga; Alena Horska; Susanne Bonekamp; Anna Mae Diehl; Frederick L Brancati; Lynne E Wagenknecht; F Xavier Pi-Sunyer; Steven E Kahn; Jeanne M Clark
Journal:  Diabetes Care       Date:  2010-07-27       Impact factor: 19.112

10.  Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review.

Authors:  R J Fontana; J L Barnett
Journal:  Am J Gastroenterol       Date:  1996-10       Impact factor: 10.864

View more
  49 in total

1.  The SCFβ-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis.

Authors:  Kouhei Shimizu; Hidefumi Fukushima; Kohei Ogura; Evan C Lien; Naoe Taira Nihira; Jinfang Zhang; Brian J North; Ailan Guo; Katsuyuki Nagashima; Tadashi Nakagawa; Seira Hoshikawa; Asami Watahiki; Koji Okabe; Aya Yamada; Alex Toker; John M Asara; Satoshi Fukumoto; Keiichi I Nakayama; Keiko Nakayama; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Sci Signal       Date:  2017-01-03       Impact factor: 8.192

2.  The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.

Authors:  Per M Hellström; Jan Tack; Lakshmi Vasist Johnson; Kimberley Hacquoil; Matthew E Barton; Duncan B Richards; David H Alpers; Gareth J Sanger; George E Dukes
Journal:  Br J Pharmacol       Date:  2016-04-13       Impact factor: 8.739

Review 3.  Hepatic glycogenosis: An underdiagnosed complication of diabetes mellitus?

Authors:  María Teresa Julián; Núria Alonso; Isabel Ojanguren; Eduarda Pizarro; Enric Ballestar; Manel Puig-Domingo
Journal:  World J Diabetes       Date:  2015-03-15

Review 4.  Diabetes and the Esophagus.

Authors:  Roberto Monreal-Robles; José M Remes-Troche
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

5.  Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  United European Gastroenterol J       Date:  2020-05-09       Impact factor: 4.623

6.  Phytobezoar leading to gastric outlet obstruction in a patient with diabetes.

Authors:  Om Prakash Dhakal; Mona Dhakal; Dhurba Bhandari
Journal:  BMJ Case Rep       Date:  2014-06-13

7.  Evaluation of liver perfusion in diabetic patients using 99mTc-sestamibi.

Authors:  Hacer Şen; Yusuf Ziya Tan; Emine Binnetoğlu; Mehmet Aşik; Fahri Güneş; Gökhan Erbağ; Emine Gazi; Sibel Cevizci; Semra Özdemir; Erdem Akbal; Kubilay Ükinç
Journal:  Wien Klin Wochenschr       Date:  2014-09-19       Impact factor: 1.704

8.  Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.

Authors:  Adam D Farmer; Anne Grave Pedersen; Birgitte Brock; Poul Erik Jakobsen; Jesper Karmisholt; Sahar D Mohammed; S Mark Scott; Asbjørn Mohr Drewes; Christina Brock
Journal:  Diabetologia       Date:  2017-01-20       Impact factor: 10.122

Review 9.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

10.  Relative Risk of Adverse Events and Treatment Discontinuations Between Older and Non-Older Adults Treated with Antimuscarinics for Overactive Bladder: A Systematic Review and Meta-Analysis.

Authors:  Silken A Usmani; Kristine Reckenberg; Olivia Johnson; Paul M Stranges; Besu F Teshome; Clark D Kebodeaux; Scott Martin Vouri
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.